Bay Street News, December, 2024

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – […]

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and […]

GUELPH, Ontario, Dec. 08, 2024 (GLOBE NEWSWIRE) — Current Water Technologies Inc. (TSX-V: WATR) (“CWTI” or “the Company” or “the Corporation“), […]

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease […]

NEWPORT NEWS, Va., Dec. 07, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) today christened Virginia-class submarine Arkansas (SSN 800) at […]

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab […]

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Rugby Resources Ltd. (“Rugby” or the “Company”) (TSX-V: RUG) is pleased […]

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on […]

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on […]